Yiheng Zhang, Xu Liu, Shu Li, Chunlei Lin, Qian Ye, Yuying Wang, Juanli Wu, Yushuang Zhang, Han Gao, Tao Li, Yundong Qu, Yan Wang. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.Hepatology communications. 2024, 8 (1):
Zobair M Younossi, Maria Stepanova, Reem Al Shabeeb, Katherine E Eberly, Dipam Shah, Veronica Nguyen, Janus Ong, Linda Henry, Saleh A Alqahtani. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.Hepatology communications. 2024, 8 (1):
Laura Brunnthaler, David Pereyra, Miriam Brenner, Jonas Santol, Lukas Herrmann, Waltraud C Schrottmaier, Anita Pirabe, Anna Schmuckenschlager, Sarang Kim, Anna Emilia Kern, Felix Xaver Huber, Lisa Emilie Michels, Christine Brostjan, Manuel Salzmann, Philipp Hohensinner, Renate Kain, Thomas Gruenberger, Patrick Starlinger, Alice Assinger. Intrahepatic neutrophil accumulation and extracellular trap formation are associated with posthepatectomy liver failure.Hepatology communications. 2024, 8 (1):
Neil Halliday, Nadia Eden, Henry Somers, Niall Burke, Hiroshi Silva, Camila Gx Brito, Andrew Hall, Alberto Quaglia, Siobhan O Burns, David M Lowe, Douglas Thorburn. Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death.Hepatology communications. 2024, 8 (1):
. Erratum: Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma.Hepatology communications. 2024, 8 (1):
Shivan J Mehta, Caitlin McDonald, Catherine Reitz, Shivani Kastuar, Christopher K Snider, Evelyn Okorie, Kiernan McNelis, Hamzah Shaikh, Tessa S Cook, David S Goldberg, Kenneth Rothstein. A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance.Hepatology communications. 2024, 8 (1):
Arun J Sanyal, Rohit Loomba, Quentin M Anstee, Vlad Ratziu, Kris V Kowdley, Mary E Rinella, Stephen A Harrison, Murray B Resnick, Thomas Capozza, Sangeeta Sawhney, Nirav Shelat, Zobair M Younossi. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.Hepatology communications. 2024, 8 (1):
Thit M Kronborg, Robert Schierwagen, Kajetan Trošt, Qian Gao, Thomas Moritz, Flemming Bendtsen, Rasmus H Gantzel, Mette L Andersen, Ane S Teisner, Henning Grønbæk, Lise Hobolth, Søren Møller, Jonel Trebicka, Nina Kimer. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.Hepatology communications. 2023, 7 (12):
Mélanie Kirchmeyer, Anthoula Gaigneaux, Florence A Servais, Anita Arslanow, Markus Casper, Marcin Krawczyk, Frank Lammert, Iris Behrmann. Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3I148M risk allele.Hepatology communications. 2023, 7 (12):
Wennan Wu, Siyi Xu, Yongbin Zeng, Luoli Yu, Tianbin Chen, Hongyan Shang, Can Liu, Bin Yang, Qishui Ou. A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population.Hepatology communications. 2023, 7 (12):
Pedro Ochoa-Allemant, Jorge A Marrero, Marina Serper. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.Hepatology communications. 2023, 7 (12):